🏅 FDA Orphan Designation
Lartruvo
olaratumab
Manufacturer: Eli Lilly and Company
Indicated for:
FDA-Approved Indications (1)
Alveolar soft tissue sarcomaOrphan Designation
In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is …
Indications & Usage
In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. (Indication withdrawn)
💙 Support Programs
View all →Lartruvo
Eli Lilly and Company
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.